Need for a comprehensive medical approach to the neuro-immuno-gastroenterology of irritable bowel syndrome

World Journal of Gastroenterology

Volumn 17, Issue 23, 2011, Pages 2791-2800

  Katiraei, Pejman ^a   Bultron, Gilberto ^a  

^a LOMA LINDA UNIVERSITY   (United States)

Author keywords

Abdominal pain; Inflammation; Irritable bowel syndrome; Probiotics; Stress

Indexed keywords

ALOSETRON; AMOXICILLIN; ANTIBIOTIC AGENT; CALCITONIN GENE RELATED PEPTIDE; CORTICOTROPIN RELEASING FACTOR; CROMOGLYCATE DISODIUM; GAMMA INTERFERON; MYOSIN LIGHT CHAIN KINASE; NERVE GROWTH FACTOR; PREBIOTIC AGENT; PROBIOTIC AGENT; PROTEIN ZO1; PROTEINASE ACTIVATED RECEPTOR 2; SEROTONIN; TEGASEROD; TUMOR NECROSIS FACTOR ALPHA;

ABDOMINAL PAIN; BACTERIAL OVERGROWTH; BIFIDOBACTERIACEAE; CAMPYLOBACTER; CANDIDA ALBICANS; CLINICAL ASSESSMENT; CLINICAL EFFECTIVENESS; CONSTIPATION; DIARRHEA; DIET RESTRICTION; DIGESTIVE SYSTEM INFLAMMATION; EGG; ENTERITIS; ESCHERICHIA COLI; GENETIC POLYMORPHISM; HUMAN; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; INTESTINE MUCOSA PERMEABILITY; IRRITABLE COLON; LACTOBACILLUS CASEI; MAST CELL; MENINGITIS; MILK; NERVE STIMULATION; NONHUMAN; OSTEOMYELITIS; OTITIS MEDIA; PATIENT CARE; PROTEIN INTAKE; PROTEIN PHOSPHORYLATION; PROTEIN TRANSPORT; REVIEW; SEPSIS; SIDE EFFECT; STRESS; VESICOURETERAL REFLUX; WHEAT;

EID: 79959633074     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v17.i23.2791     Document Type: Review

References (202)

1. Appendix A Rome III Diagnostic Criteria for Functional Gastrointestinal Disorders, pg 889 accessed 8/22/09. Available from: URL: http://www.romecriteria.org
2. Hyams JS, Burke G, Davis PM, Rzepski B, Andrulonis PA. Abdominal pain and irritable bowel syndrome in adolescents: a community-based study. J Pediatr 1996; 129: 220-226
3. Hyams JS, Treem WR, Justinich CJ, Davis P, Shoup M, Burke G. Characterization of symptoms in children with recurrent abdominal pain: resemblance to irritable bowel syndrome. J Pediatr Gastroenterol Nutr 1995; 20: 209-214
4. Christensen MF, Mortensen O. Long-term prognosis in children with recurrent abdominal pain. Arch Dis Child 1975; 50: 110-114
5. Frank L, Kleinman L, Rentz A, Ciesla G, Kim JJ, Zacker C. Health-related quality of life associated with irritable bowel syndrome: comparison with other chronic diseases. Clin Ther 2002; 24: 675-689; discussion 674
6. Creed F, Ratcliffe J, Fernandez L, Tomenson B, Palmer S, Rigby C, Guthrie E, Read N, Thompson D. Health-related quality of life and health care costs in severe, refractory irritable bowel syndrome. Ann Intern Med 2001; 134: 860-868
7. Longstreth GF, Yao JF. Irritable bowel syndrome and surgery: a multivariable analysis. Gastroenterology 2004; 126: 1665-1673
8. Hasler WL, Schoenfeld P. Systematic review: Abdominal and pelvic surgery in patients with irritable bowel syndrome. Aliment Pharmacol Ther 2003; 17: 997-1005
9. Talley NJ. Unnecessary abdominal and back surgery in irritable bowel syndrome: time to stem the food now? Gastro-enterology 2004; 126: 1899-1903
10. Longstreth GF. Avoiding unnecessary surgery in irritable bowel syndrome. Gut 2007; 56: 608-610
11. Talley NJ, Gabriel SE, Harmsen WS, Zinsmeister AR, Evans RW. Medical costs in community subjects with irritable bowel syndrome. Gastroenterology 1995; 109: 1736-1741
12. Leong SA, Barghout V, Birnbaum HG, Thibeault CE, Ben-Hamadi R, Frech F, Ofman JJ. The economic consequences of irritable bowel syndrome: a US employer perspective. Arch Intern Med 2003; 163: 929-935
13. Lane MM, Weidler EM, Czyzewski DI, Shulman RJ. Pain symptoms and stooling patterns do not drive diagnostic costs for children with functional abdominal pain and irritable bowel syndrome in primary or tertiary care. Pediatrics 2009; 123: 758-764
14. Longstreth GF, Wilson A, Knight K, Wong J, Chiou CF, Barghout V, Frech F, Ofman JJ. Irritable bowel syndrome, health care use, and costs: a U.S. managed care perspective. Am J Gastroenterol 2003; 98: 600-607
15. Maxion-Bergemann S, Thielecke F, Abel F, Bergemann R. Costs of irritable bowel syndrome in the UK and US. Phar-macoeconomics 2006; 24: 21-37
16. Ford AC, Talley NJ, Schoenfeld PS, Quigley EM, Moayyedi P. Efficacy of antidepressants and psychological therapies in irritable bowel syndrome: systematic review and meta-analysis. Gut 2009; 58: 367-378
17. Chronic abdominal pain in children. Pediatrics 2005; 115: 812-815
18. White DL, Savas LS, Daci K, Elserag R, Graham DP, Fitzgerald SJ, Smith SL, Tan G, El-Serag HB. Trauma history and risk of the irritable bowel syndrome in women veterans. Aliment Pharmacol Ther 2010; 32: 551-561
19. Spiller R, Garsed K. Postinfectious irritable bowel syndrome. Gastroenterology 2009; 136: 1979-1988
20. Alonso C, Guilarte M, Vicario M, Ramos L, Ramadan Z, Antoln M, Martnez C, Rezzi S, Saperas E, Kochhar S, Santos J, Malagelada JR. Maladaptive intestinal epithelial responses to life stress may predispose healthy women to gut mucosal inflammation. Gastroenterology 2008; 135: 163-172.e1
21. Walker LS, Garber J, Smith CA, Van Slyke DA, Claar RL. The relation of daily stressors to somatic and emotional symptoms in children with and without recurrent abdominal pain. J Consult Clin Psychol 2001; 69: 85-91
22. Kiank C, Tach Y, Larauche M. Stress-related modulation of inflammation in experimental models of bowel disease and post-infectious irritable bowel syndrome: role of corticotropin-releasing factor receptors. Brain Behav Immun 2010; 24: 41-48
23. Gareau MG, Silva MA, Perdue MH. Pathophysiological mechanisms of stress-induced intestinal damage. Curr Mol Med 2008; 8: 274-281
24. Posserud I, Agerforz P, Ekman R, Bjrnsson ES, Abrahams-son H, Simrn M. Altered visceral perceptual and neuroen-docrine response in patients with irritable bowel syndrome during mental stress. Gut 2004; 53: 1102-1108
25. Gareau MG, Jury J, Yang PC, MacQueen G, Perdue MH. Neonatal maternal separation causes colonic dysfunction in rat pups including impaired host resistance. Pediatr Res 2006; 59: 83-88
26. Mazzon E, Sturniolo GC, Puzzolo D, Frisina N, Fries W. Effect of stress on the paracellular barrier in the rat ileum. Gut 2002; 51: 507-513
27. Zareie M, Johnson-Henry K, Jury J, Yang PC, Ngan BY, McKay DM, Soderholm JD, Perdue MH, Sherman PM. Pro-biotics prevent bacterial translocation and improve intestinal barrier function in rats following chronic psychological stress. Gut 2006; 55: 1553-1560
28. Barreau F, Cartier C, Leveque M, Ferrier L, Moriez R, Laroute V, Rosztoczy A, Fioramonti J, Bueno L. Pathways involved in gut mucosal barrier dysfunction induced in adult rats by maternal deprivation: corticotrophin-releasing factor and nerve growth factor interplay. J Physiol 2007; 580: 347-356
29. Gareau MG, Jury J, Perdue MH. Neonatal maternal separation of rat pups results in abnormal cholinergic regulation of epithelial permeability. Am J Physiol Gastrointest Liver Physiol 2007; 293: G198-G203
30. Piche T, Saint-Paul MC, Dainese R, Marine-Barjoan E, Ian-nelli A, Montoya ML, Peyron JF, Czerucka D, Cherikh F, Filippi J, Tran A, Hbuterne X. Mast cells and cellularity of the colonic mucosa correlated with fatigue and depression in irritable bowel syndrome. Gut 2008; 57: 468-473
31. Rijnierse A, Nijkamp FP, Kraneveld AD. Mast cells and nerves tickle in the tummy: implications for inflammatory bowel disease and irritable bowel syndrome. Pharmacol Ther 2007; 116: 207-235
32. Farhadi A, Fields JZ, Keshavarzian A. Mucosal mast cells are pivotal elements in inflammatory bowel disease that connect the dots: stress, intestinal hyperpermeability and inflammation. World J Gastroenterol 2007; 13: 3027-3030
33. Wallon C, Yang PC, Keita AV, Ericson AC, McKay DM, Sherman PM, Perdue MH, Sderholm JD. Corticotropin-releasing hormone (CRH) regulates macromolecular permeability via mast cells in normal human colonic biopsies in vitro. Gut 2008; 57: 50-58
34. Santos J, Saunders PR, Hanssen NP, Yang PC, Yates D, Groot JA, Perdue MH. Corticotropin-releasing hormone mimics stress-induced colonic epithelial pathophysiology in the rat. Am J Physiol 1999; 277: G391-G399
35. Saunders PR, Santos J, Hanssen NP, Yates D, Groot JA, Perdue MH. Physical and psychological stress in rats enhances colonic epithelial permeability via peripheral CRH. Dig Dis Sci 2002; 47: 208-215
36. Pothoulakis C, Castagliuolo I, Leeman SE. Neuroimmune mechanisms of intestinal responses to stress. Role of corti-cotropin-releasing factor and neurotensin. Ann N Y Acad Sci 1998; 840: 635-648
37. Castagliuolo I, Lamont JT, Qiu B, Fleming SM, Bhaskar KR, Nikulasson ST, Kornetsky C, Pothoulakis C. Acute stress causes mucin release from rat colon: role of corticotropin releasing factor and mast cells. Am J Physiol 1996; 271: G884-G892
38. Miceli PC, Jacobson K. Cholinergic pathways modulate experimental dinitrobenzene sulfonic acid colitis in rats. Auton Neurosci 2003; 105: 16-24
39. Stead RH, Tomioka M, Quinonez G, Simon GT, Felten SY, Bienenstock J. Intestinal mucosal mast cells in normal and nematode-infected rat intestines are in intimate contact with peptidergic nerves. Proc Natl Acad Sci USA 1987; 84: 2975-2979
40. Santos J, Guilarte M, Alonso C, Malagelada JR. Pathogenesis of irritable bowel syndrome: the mast cell connection. Scand J Gastroenterol 2005; 40: 129-140
41. De Jonge F, De Laet A, Van Nassauw L, Brown JK, Miller HR, van Bogaert PP, Timmermans JP, Kroese AB. In vitro activation of murine DRG neurons by CGRP-mediated mu-cosal mast cell degranulation. Am J Physiol Gastrointest Liver Physiol 2004; 287: G178-G191
42. Janiszewski J, Bienenstock J, Blennerhassett MG. Picomolar doses of substance P trigger electrical responses in mast cells without degranulation. Am J Physiol 1994; 267: C138-C145
43. Stead RH, Colley EC, Wang B, Partosoedarso E, Lin J, Stan-isz A, Hillsley K. Vagal influences over mast cells. Auton Neurosci 2006; 125: 53-61
44. Wang L, Stanisz AM, Wershil BK, Galli SJ, Perdue MH. Substance P induces ion secretion in mouse small intestine through effects on enteric nerves and mast cells. Am J Physi-ol 1995; 269: G85-G92
45. Stead RH, Kosecka-Janiszewska U, Oestreicher AB, Dixon MF, Bienenstock J. Remodeling of B-50 (GAP-43)- and NSE-immunoreactive mucosal nerves in the intestines of rats infected with Nippostrongylus brasiliensis. J Neurosci 1991; 11: 3809-3821
46. Wang LH, Fang XC, Pan GZ. Bacillary dysentery as a causative factor of irritable bowel syndrome and its pathogen-esis. Gut 2004; 53: 1096-1101
47. Di Sebastiano P, Fink T, Weihe E, Friess H, Beger HG, Bchler M. Changes of protein gene product 9.5 (PGP 9.5) immunoreactive nerves in inflamed appendix. Dig Dis Sci 1995; 40: 366-372
48. Leonard N, Hourihane DO, Whelan A. Neuroproliferation in the mucosa is a feature of coeliac disease and Crohn's disease. Gut 1995; 37: 763-765
49. Barreau F, Salvador-Cartier C, Houdeau E, Bueno L, Fiora-monti J. Long-term alterations of colonic nerve-mast cell interactions induced by neonatal maternal deprivation in rats. Gut 2008; 57: 582-590
50. Stead RH. Nerve remodelling during intestinal inflammation. Ann N Y Acad Sci 1992; 664: 443-455
51. Burgos I, Cuello AC, Liberini P, Pioro E, Masliah E. NGF-mediated synaptic sprouting in the cerebral cortex of le-sioned primate brain. Brain Res 1995; 692: 154-160
52. Leon A, Buriani A, Dal Toso R, Fabris M, Romanello S, Aloe L, Levi-Montalcini R. Mast cells synthesize, store, and release nerve growth factor. Proc Natl Acad Sci USA 1994; 91: 3739-3743
53. Saunders PR, Miceli P, Vallance BA, Wang L, Pinto S, Tou-gas G, Kamath M, Jacobson K. Noradrenergic and cholinergic neural pathways mediate stress-induced reactivation of colitis in the rat. Auton Neurosci 2006; 124: 56-68
54. Lantz CS, Huff TF. Differential responsiveness of purified mouse c-kit mast cells and their progenitors to IL-3 and stem cell factor. J Immunol 1995; 155: 4024-4029
55. Rennick D, Hunte B, Holland G, Thompson-Snipes L. Co-factors are essential for stem cell factor-dependent growth and maturation of mast cell progenitors: comparative effects of interleukin-3 (IL-3), IL-4, IL-10, and fibroblasts. Blood 1995; 85: 57-65
56. Nakahata T, Toru H. Cytokines regulate development of human mast cells from hematopoietic progenitors. Int J He-matol 2002; 75: 350-356
57. Blennerhassett MG, Bienenstock J. Sympathetic nerve contact causes maturation of mast cells in vitro. J Neurobiol 1998; 35: 173-182
58. Barbara G, De Giorgio R, Stanghellini V, Cremon C, Cori-naldesi R. A role for inflammation in irritable bowel syndrome? Gut 2002; 51 Suppl 1: i41-i44
59. Theoharides TC, Donelan JM, Papadopoulou N, Cao J, Kempuraj D, Conti P. Mast cells as targets of corticotropin-releasing factor and related peptides. Trends Pharmacol Sci 2004; 25: 563-568
60. Saito-Nakaya K, Hasegawa R, Nagura Y, Ito H, Fukudo S. Corticotropin-releasing hormone receptor 1 antagonist blocks colonic hypersensitivity induced by a combination of inflammation and repetitive colorectal distension. Neurogas-troenterol Motil 2008; 20: 1147-1156
61. Gross KJ, Pothoulakis C. Role of neuropeptides in inflammatory bowel disease. Infamm Bowel Dis 2007; 13: 918-932
62. Chadwick VS, Chen W, Shu D, Paulus B, Bethwaite P, Tie A, Wilson I. Activation of the mucosal immune system in irritable bowel syndrome. Gastroenterology 2002; 122: 1778-1783
63. Cremon C, Gargano L, Morselli-Labate AM, Santini D, Co-gliandro RF, De Giorgio R, Stanghellini V, Corinaldesi R, Barbara G. Mucosal immune activation in irritable bowel syndrome: gender-dependence and association with digestive symptoms. Am J Gastroenterol 2009; 104: 392-400
64. Singh VK. Stimulatory effect of corticotropin-releasing neu-rohormone on human lymphocyte proliferation and interleu-kin-2 receptor expression. J Neuroimmunol 1989; 23: 257-262
65. Agelaki S, Tsatsanis C, Gravanis A, Margioris AN. Cortico-tropin-releasing hormone augments proinflammatory cyto-kine production from macrophages in vitro and in lipopoly-saccharide-induced endotoxin shock in mice. Infect Immun 2002; 70: 6068-6074
66. Black PH. Stress and the inflammatory response: a review of neurogenic inflammation. Brain Behav Immun 2002; 16: 622-653
67. He S, Peng Q, Walls AF. Potent induction of a neutrophil and eosinophil-rich infiltrate in vivo by human mast cell tryptase: selective enhancement of eosinophil recruitment by histamine. J Immunol 1997; 159: 6216-6225
68. Verne GN, Himes NC, Robinson ME, Gopinath KS, Briggs RW, Crosson B, Price DD. Central representation of visceral and cutaneous hypersensitivity in the irritable bowel syndrome. Pain 2003; 103: 99-110
69. Silverman DH, Munakata JA, Ennes H, Mandelkern MA, Hoh CK, Mayer EA. Regional cerebral activity in normal and pathological perception of visceral pain. Gastroenterol-ogy 1997; 112: 64-72
70. Verne GN, Price DD. Irritable bowel syndrome as a common precipitant of central sensitization. Curr Rheumatol Rep 2002; 4: 322-328
71. Price DD, Zhou Q, Moshiree B, Robinson ME, Verne GN. Peripheral and central contributions to hyperalgesia in irritable bowel syndrome. J Pain 2006; 7: 529-535
72. Al-Chaer ED, Kawasaki M, Pasricha PJ. A new model of chronic visceral hypersensitivity in adult rats induced by colon irritation during postnatal development. Gastroenterol-ogy 2000; 119: 1276-1285
73. De Giorgio R, Barbara G. Is irritable bowel syndrome an inflammatory disorder? Curr Gastroenterol Rep 2008; 10: 385-390
74. Park JH, Rhee PL, Kim HS, Lee JH, Kim YH, Kim JJ, Rhee JC. Mucosal mast cell counts correlate with visceral hyper-sensitivity in patients with diarrhea predominant irritable bowel syndrome. J Gastroenterol Hepatol 2006; 21: 71-78
75. Barbara G, Stanghellini V, De Giorgio R, Cremon C, Cottrell GS, Santini D, Pasquinelli G, Morselli-Labate AM, Grady EF, Bunnett NW, Collins SM, Corinaldesi R. Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome. Gastroenterology 2004; 126: 693-702
76. Barbara G, Wang B, Stanghellini V, de Giorgio R, Cremon C, Di Nardo G, Trevisani M, Campi B, Geppetti P, Tonini M, Bunnett NW, Grundy D, Corinaldesi R. Mast cell-dependent excitation of visceral-nociceptive sensory neurons in irritable bowel syndrome. Gastroenterology 2007; 132: 26-37
77. Buhner S, Li Q, Vignali S, Barbara G, De Giorgio R, Stang-hellini V, Cremon C, Zeller F, Langer R, Daniel H, Michel K, Schemann M. Activation of human enteric neurons by supernatants of colonic biopsy specimens from patients with irritable bowel syndrome. Gastroenterology 2009; 137: 1425-1434
78. Cenac N, Andrews CN, Holzhausen M, Chapman K, Cot-trell G, Andrade-Gordon P, Steinhoff M, Barbara G, Beck P, Bunnett NW, Sharkey KA, Ferraz JG, Shaffer E, Vergnolle N. Role for protease activity in visceral pain in irritable bowel syndrome. J Clin Invest 2007; 117: 636-647
79. Ossovskaya VS, Bunnett NW. Protease-activated receptors: contribution to physiology and disease. Physiol Rev 2004; 84: 579-621
80. Moshiree B, Zhou Q, Price DD, Verne GN. Central sensitisation in visceral pain disorders. Gut 2006; 55: 905-908
81. Verne GN, Robinson ME, Price DD. Hypersensitivity to visceral and cutaneous pain in the irritable bowel syndrome. Pain 2001; 93: 7-14
82. Seybold VS. The role of peptides in central sensitization. Handb Exp Pharmacol 2009; 451-491
83. Yeo A, Boyd P, Lumsden S, Saunders T, Handley A, Stub-bins M, Knaggs A, Asquith S, Taylor I, Bahari B, Crocker N, Rallan R, Varsani S, Montgomery D, Alpers DH, Dukes GE, Purvis I, Hicks GA. Association between a functional polymorphism in the serotonin transporter gene and diarrhoea predominant irritable bowel syndrome in women. Gut 2004; 53: 1452-1458
84. Spiller R. Serotonin, inflammation, and IBS: fitting the jigsaw together? J Pediatr Gastroenterol Nutr 2007; 45 Suppl 2: S115-S119
85. Kim DY, Camilleri M. Serotonin: a mediator of the brain-gut connection. Am J Gastroenterol 2000; 95: 2698-2709
86. Lesurtel M, Soll C, Graf R, Clavien PA. Role of serotonin in the hepato-gastroIntestinal tract: an old molecule for new perspectives. Cell Mol Life Sci 2008; 65: 940-952
87. Gershon MD. Review article: roles played by 5-hydroxy-tryptamine in the physiology of the bowel. Aliment Pharmacol Ther 1999; 13 Suppl 2: 15-30
88. Crowell MD. The role of serotonin in the pathophysiol-ogy of irritable bowel syndrome. Am J Manag Care 2001; 7: S252-S260
89. Crowell MD. Role of serotonin in the pathophysiology of the irritable bowel syndrome. Br J Pharmacol 2004; 141: 1285-1293
90. Sikander A, Rana SV, Prasad KK. Role of serotonin in gastrointestinal motility and irritable bowel syndrome. Clin Chim Acta 2009; 403: 47-55
91. Spiller RC. Postinfectious irritable bowel syndrome. Gastro-enterology 2003; 124: 1662-1671
92. Spiller RC, Jenkins D, Thornley JP, Hebden JM, Wright T, Skinner M, Neal KR. Increased rectal mucosal enteroendo-crine cells, T lymphocytes, and increased gut permeability following acute Campylobacter enteritis and in post-dysenteric irritable bowel syndrome. Gut 2000; 47: 804-811
93. Dunlop SP, Jenkins D, Neal KR, Spiller RC. Relative importance of enterochromaffn cell hyperplasia, anxiety, and depression in postinfectious IBS. Gastroenterology 2003; 125: 1651-1659
94. Wang H, Steeds J, Motomura Y, Deng Y, Verma-Gandhu M, El-Sharkawy RT, McLaughlin JT, Grencis RK, Khan WI. CD4T cell-mediated immunological control of enterochro-maffn cell hyperplasia and 5-hydroxytryptamine production in enteric infection. Gut 2007; 56: 949-957
95. Atkinson W, Lockhart S, Whorwell PJ, Keevil B, Houghton LA. Altered 5-hydroxytryptamine signaling in patients with constipation- and diarrhea-predominant irritable bowel syndrome. Gastroenterology 2006; 130: 34-43
96. Chen JX, Pan H, Rothman TP, Wade PR, Gershon MD. Guinea pig 5-HT transporter: cloning, expression, distribution, and function in intestinal sensory reception. Am J Physiol 1998; 275: G433-G448
97. Wade PR, Chen J, Jaffe B, Kassem IS, Blakely RD, Gershon MD. Localization and function of a 5-HT transporter in crypt epithelia of the gastrointestinal tract. J Neurosci 1996; 16: 2352-2364
98. Coates MD, Mahoney CR, Linden DR, Sampson JE, Chen J, Blaszyk H, Crowell MD, Sharkey KA, Gershon MD, Mawe GM, Moses PL. Molecular defects in mucosal serotonin content and decreased serotonin reuptake transporter in ulcerative colitis and irritable bowel syndrome. Gastroenterology 2004; 126: 1657-1664
99. Kohen R, Jarrett ME, Cain KC, Jun SE, Navaja GP, Symonds S, Heitkemper MM. The serotonin transporter polymorphism rs25531 is associated with irritable bowel syndrome. Dig Dis Sci 2009; 54: 2663-2670
100. Mawe GM, Coates MD, Moses PL. Review article: intestinal serotonin signalling in irritable bowel syndrome. Aliment Pharmacol Ther 2006; 23: 1067-1076
101. Kraehenbuhl JP, Corbett M. Immunology. Keeping the gut microfora at bay. Science 2004; 303: 1624-1625
102. Kong W, McConalogue K, Khitin LM, Hollenberg MD, Payan DG, Bhm SK, Bunnett NW. Luminal trypsin may regulate enterocytes through proteinase-activated receptor 2. Proc Natl Acad Sci USA 1997; 94: 8884-8889
103. Cenac N, Chin AC, Garcia-Villar R, Salvador-Cartier C, Fer-rier L, Vergnolle N, Buret AG, Fioramonti J, Bueno L. PAR2 activation alters colonic paracellular permeability in mice via IFN-gamma-dependent and -independent pathways. J Physiol 2004; 558: 913-925
104. Ferrier L, Mazelin L, Cenac N, Desreumaux P, Janin A, Emi-lie D, Colombel JF, Garcia-Villar R, Fioramonti J, Bueno L. Stress-induced disruption of colonic epithelial barrier: role of interferon-gamma and myosin light chain kinase in mice. Gastroenterology 2003; 125: 795-804
105. Ye D, Ma I, Ma TY. Molecular mechanism of tumor necrosis factor-alpha modulation of intestinal epithelial tight junction barrier. Am J Physiol Gastrointest Liver Physiol 2006; 290: G496-G504
106. Ma TY, Boivin MA, Ye D, Pedram A, Said HM. Mechanism of TNF-{alpha} modulation of Caco-2 intestinal epithelial tight junction barrier: role of myosin light-chain kinase protein expression. Am J Physiol Gastrointest Liver Physiol 2005; 288: G422-G430
107. Dunlop SP, Hebden J, Campbell E, Naesdal J, Olbe L, Perkins AC, Spiller RC. Abnormal intestinal permeability in subgroups of diarrhea-predominant irritable bowel syndromes. Am J Gastroenterol 2006; 101: 1288-1294
108. Barau E, Dupont C. Modifications of intestinal permeability during food provocation procedures in pediatric irritable bowel syndrome. J Pediatr Gastroenterol Nutr 1990; 11: 72-77
109. Barbara G. Mucosal barrier defects in irritable bowel syndrome. Who left the door open? Am J Gastroenterol 2006; 101: 1295-1298
110. Rautava S, Walker WA. Commensal bacteria and epithelial cross talk in the developing intestine. Curr Gastroenterol Rep 2007; 9: 385-392
111. Tlaskalova-Hogenova H, Tuckova L, Mestecky J, Kolinska J, Rossmann P, Stepankova R, Kozakova H, Hudcovic T, Hrncir T, Frolova L, Kverka M. Interaction of mucosal mi-crobiota with the innate immune system. Scand J Immunol 2005; 62 Suppl 1: 106-113
112. Kelly D, Conway S. Bacterial modulation of mucosal innate immunity. Mol Immunol 2005; 42: 895-901
113. Taurog JD, Richardson JA, Croft JT, Simmons WA, Zhou M, Fernndez-Sueiro JL, Balish E, Hammer RE. The germfree state prevents development of gut and joint inflammatory disease in HLA-B27 transgenic rats. J Exp Med 1994; 180: 2359-2364
114. Sellon RK, Tonkonogy S, Schultz M, Dieleman LA, Gren-ther W, Balish E, Rennick DM, Sartor RB. Resident enteric bacteria are necessary for development of spontaneous colitis and immune system activation in interleukin-10-defcient mice. Infect Immun 1998; 66: 5224-5231
115. Rath HC, Herfarth HH, Ikeda JS, Grenther WB, Hamm TE, Balish E, Taurog JD, Hammer RE, Wilson KH, Sartor RB. Normal luminal bacteria, especially Bacteroides species, mediate chronic colitis, gastritis, and arthritis in HLA-B27/hu-man beta2 microglobulin transgenic rats. J Clin Invest 1996; 98: 945-953
116. Schoepfer AM, Schaffer T, Seibold-Schmid B, Mller S, Sei-bold F. Antibodies to fagellin indicate reactivity to bacterial antigens in IBS patients. Neurogastroenterol Motil 2008; 20: 1110-1118
117. Rachmilewitz D, Katakura K, Karmeli F, Hayashi T, Reinus C, Rudensky B, Akira S, Takeda K, Lee J, Takabayashi K, Raz E. Toll-like receptor 9 signaling mediates the anti-inflammatory effects of probiotics in murine experimental colitis. Gastroen-terology 2004; 126: 520-528
118. Jijon H, Backer J, Diaz H, Yeung H, Thiel D, McKaigney C, De Simone C, Madsen K. DNA from probiotic bacteria modulates murine and human epithelial and immune function. Gastroenterology 2004; 126: 1358-1373
119. Yuhan R, Koutsouris A, Savkovic SD, Hecht G. Entero-pathogenic Escherichia coli-induced myosin light chain phosphorylation alters intestinal epithelial permeability. Gastroenterology 1997; 113: 1873-1882
120. Mangell P, Nejdfors P, Wang M, Ahrn S, Westrm B, Thor-lacius H, Jeppsson B. Lactobacillus plantarum 299v inhibits Escherichia coli-induced intestinal permeability. Dig Dis Sci 2002; 47: 511-516
121. Spitz J, Yuhan R, Koutsouris A, Blatt C, Alverdy J, Hecht G. Enteropathogenic Escherichia coli adherence to intestinal epithelial monolayers diminishes barrier function. Am J Physiol 1995; 268: G374-G379
122. McCarthy J, O'Mahony L, O'Callaghan L, Sheil B, Vaughan EE, Fitzsimons N, Fitzgibbon J, O'Sullivan GC, Kiely B, Collins JK, Shanahan F. Double blind, placebo controlled trial of two probiotic strains in interleukin 10 knockout mice and mechanistic link with cytokine balance. Gut 2003; 52: 975-980
123. Zoumpopoulou G, Foligne B, Christodoulou K, Grangette C, Pot B, Tsakalidou E. Lactobacillus fermentum ACA-DC 179 displays probiotic potential in vitro and protects against trinitrobenzene sulfonic acid (TNBS)-induced colitis and Salmonella infection in murine models. Int J Food Microbiol 2008; 121: 18-26
124. Peran L, Sierra S, Comalada M, Lara-Villoslada F, Bailn E, Nieto A, Concha A, Olivares M, Zarzuelo A, Xaus J, Glvez J. A comparative study of the preventative effects exerted by two probiotics, Lactobacillus reuteri and Lactobacillus fermentum, in the trinitrobenzenesulfonic acid model of rat colitis. Br J Nutr 2007; 97: 96-103
125. Madsen K, Cornish A, Soper P, McKaigney C, Jijon H, Yachimec C, Doyle J, Jewell L, De Simone C. Probiotic bacteria enhance murine and human intestinal epithelial barrier function. Gastroenterology 2001; 121: 580-591
126. Gopal PK, Prasad J, Smart J, Gill HS. In vitro adherence properties of Lactobacillus rhamnosus DR20 and Bifdobac-terium lactis DR10 strains and their antagonistic activity against an enterotoxigenic Escherichia coli. Int J Food Micro-biol 2001; 67: 207-216
127. Mangell P, Lennerns P, Wang M, Olsson C, Ahrn S, Molin G, Thorlacius H, Jeppsson B. Adhesive capability of Lactoba-cillus plantarum 299v is important for preventing bacterial translocation in endotoxemic rats. APMIS 2006; 114: 611-618
128. Verd EF, Bercik P, Verma-Gandhu M, Huang XX, Blenne-rhassett P, Jackson W, Mao Y, Wang L, Rochat F, Collins SM. Specific probiotic therapy attenuates antibiotic induced visceral hypersensitivity in mice. Gut 2006; 55: 182-190
129. Liebregts T, Adam B, Bertel A, Jones S, Schulze J, Enders C, Sonnenborn U, Lackner K, Holtmann G. Effect of E. coli Nissle 1917 on post-inflammatory visceral sensory function in a rat model. Neurogastroenterol Motil 2005; 17: 410-414
130. Eutamene H, Lamine F, Chabo C, Theodorou V, Rochat F, Bergonzelli GE, Corthsy-Theulaz I, Fioramonti J, Bueno L. Synergy between Lactobacillus paracasei and its bacterial products to counteract stress-induced gut permeability and sensitivity increase in rats. J Nutr 2007; 137: 1901-1907
131. Ait-Belgnaoui A, Eutamene H, Houdeau E, Bueno L, Fiora-monti J, Theodorou V. Lactobacillus farciminis treatment attenuates stress-induced overexpression of Fos protein in spinal and supraspinal sites after colorectal distension in rats. Neurogastroenterol Motil 2009; 21: 567-573, e18-e19
132. Rousseaux C, Thuru X, Gelot A, Barnich N, Neut C, Dubu-quoy L, Dubuquoy C, Merour E, Geboes K, Chamaillard M, Ouwehand A, Leyer G, Carcano D, Colombel JF, Ardid D, Desreumaux P. Lactobacillus acidophilus modulates intestinal pain and induces opioid and cannabinoid receptors. Nat Med 2007; 13: 35-37
133. Hoveyda N, Heneghan C, Mahtani KR, Perera R, Roberts N, Glasziou P. A systematic review and meta-analysis: pro-biotics in the treatment of irritable bowel syndrome. BMC Gastroenterol 2009; 9: 15
134. Barbara G, Stanghellini V, Cremon C, De Giorgio R, Garga-no L, Cogliandro R, Pallotti F, Corinaldesi R. Probiotics and irritable bowel syndrome: rationale and clinical evidence for their use. J Clin Gastroenterol 2008; 42 Suppl 3 Pt 2: S214-S217
135. Kassinen A, Krogius-Kurikka L, Mkivuokko H, Rinttil T, Paulin L, Corander J, Malinen E, Apajalahti J, Palva A. The fecal microbiota of irritable bowel syndrome patients differs significantly from that of healthy subjects. Gastroenterology 2007; 133: 24-33
136. Dubos R, Schaedler RW, Stephens M. The effect of antibacterial drugs on the fecal fora of mice. J Exp Med 1963; 117: 231-243
137. Sullivan A, Edlund C, Nord CE. Effect of antimicrobial agents on the ecological balance of human microfora. Lancet Infect Dis 2001; 1: 101-114
138. Edlund C, Nord CE. Effect on the human normal microfora of oral antibiotics for treatment of urinary tract infections. J Antimicrob Chemother 2000; 46 Suppl 1: 41-48; discussion 63-65
139. Mendall MA, Kumar D. Antibiotic use, childhood affluence and irritable bowel syndrome (IBS). Eur J Gastroenterol Hepa-tol 1998; 10: 59-62
140. Maxwell PR, Rink E, Kumar D, Mendall MA. Antibiotics increase functional abdominal symptoms. Am J Gastroenterol 2002; 97: 104-108
141. Blaut M. Relationship of prebiotics and food to intestinal microfora. Eur J Nutr 2002; 41 Suppl 1: I11-I16
142. Delzenne NM. Oligosaccharides: state of the art. Proc Nutr Soc 2003; 62: 177-182
143. Gibson GR. Dietary modulation of the human gut microfo-ra using the prebiotics oligofructose and inulin. J Nutr 1999; 129: 1438S-1441S
144. Giannini EG, Mansi C, Dulbecco P, Savarino V. Role of partially hydrolyzed guar gum in the treatment of irritable bowel syndrome. Nutrition 2006; 22: 334-342
145. Silk DB, Davis A, Vulevic J, Tzortzis G, Gibson GR. Clinical trial: the effects of a trans-galactooligosaccharide prebiotic on faecal microbiota and symptoms in irritable bowel syndrome. Aliment Pharmacol Ther 2009; 29: 508-518
146. Paineau D, Payen F, Panserieu S, Coulombier G, Sobaszek A, Lartigau I, Brabet M, Galmiche JP, Tripodi D, Sacher-Huvelin S, Chapalain V, Zourabichvili O, Respondek F, Wagner A, Bornet FR. The effects of regular consumption of short-chain fructo-oligosaccharides on digestive comfort of subjects with minor functional bowel disorders. Br J Nutr 2008; 99: 311-318
147. Macfarlane S, Macfarlane GT, Cummings JH. Review article: prebiotics in the gastrointestinal tract. Aliment Pharmacol Ther 2006; 24: 701-714
148. Newburg DS. Oligosaccharides in human milk and bacterial colonization. J Pediatr Gastroenterol Nutr 2000; 30 Suppl 2: S8-S17
149. Marshall JS. Repeated antigen challenge in rats induces a mucosal mast cell hyperplasia. Gastroenterology 1993; 105: 391-398
150. Barau E, Dupont C. Modifications of intestinal permeability during food provocation procedures in pediatric irritable bowel syndrome. J Pediatr Gastroenterol Nutr 1990; 11: 72-77
151. Grazioli I, Melzi G, Balsamo V, Castellucci G, Castro M, Catassi C, Rtsch JM, Scotta S. [Food intolerance and irritable bowel syndrome of childhood: clinical efficacy of oral sodium cromoglycate and elimination diet]. Minerva Pediatr 1993; 45: 253-258
152. Lunardi C, Bambara LM, Biasi D, Cortina P, Peroli P, Nico-lis F, Favari F, Pacor ML. Double-blind cross-over trial of oral sodium cromoglycate in patients with irritable bowel syndrome due to food intolerance. Clin Exp Allergy 1991; 21: 569-572
153. Stefanini GF, Prati E, Albini MC, Piccinini G, Capelli S, Castelli E, Mazzetti M, Gasbarrini G. Oral disodium cro-moglycate treatment on irritable bowel syndrome: an open study on 101 subjects with diarrheic type. Am J Gastroenterol 1992; 87: 55-57
154. Zar S, Kumar D, Benson MJ. Food hypersensitivity and irritable bowel syndrome. Aliment Pharmacol Ther 2001; 15: 439-449
155. Monsbakken KW, Vandvik PO, Farup PG. Perceived food intolerance in subjects with irritable bowel syndrome-- etiology, prevalence and consequences. Eur J Clin Nutr 2006; 60: 667-672
156. Dainese R, Galliani EA, De Lazzari F, Di Leo V, Naccarato R. Discrepancies between reported food intolerance and sensitization test findings in irritable bowel syndrome patients. Am J Gastroenterol 1999; 94: 1892-1897
157. Nanda R, James R, Smith H, Dudley CR, Jewell DP. Food intolerance and the irritable bowel syndrome. Gut 1989; 30: 1099-1104
158. Teufel M, Biedermann T, Rapps N, Hausteiner C, Hen-ningsen P, Enck P, Zipfel S. Psychological burden of food allergy. World J Gastroenterol 2007; 13: 3456-3465
159. Heizer WD, Southern S, McGovern S. The role of diet in symptoms of irritable bowel syndrome in adults: a narrative review. J Am Diet Assoc 2009; 109: 1204-1214
160. Rief W, Barsky AJ. Psychobiological perspectives on somato-form disorders. Psychoneuroendocrinology 2005; 30: 996-1002
161. Farah DA, Calder I, Benson L, MacKenzie JF. Specific food intolerance: its place as a cause of gastrointestinal symptoms. Gut 1985; 26: 164-168
162. Bernstein M, Day JH, Welsh A. Double-blind food challenge in the diagnosis of food sensitivity in the adult. J Allergy Clin Immunol 1982; 70: 205-210
163. Niec AM, Frankum B, Talley NJ. Are adverse food reactions linked to irritable bowel syndrome? Am J Gastroenterol 1998; 93: 2184-2190
164. Atkinson W, Sheldon TA, Shaath N, Whorwell PJ. Food elimination based on IgG antibodies in irritable bowel syndrome: a randomised controlled trial. Gut 2004; 53: 1459-1464
165. Zar S, Mincher L, Benson MJ, Kumar D. Food-specific IgG4 antibody-guided exclusion diet improves symptoms and rectal compliance in irritable bowel syndrome. Scand J Gas-troenterol 2005; 40: 800-807
166. Stefanini GF, Saggioro A, Alvisi V, Angelini G, Capurso L, di Lorenzo G, Dobrilla G, Dodero M, Galimberti M, Gas-barrini G. Oral cromolyn sodium in comparison with elimination diet in the irritable bowel syndrome, diarrheic type. Multicenter study of 428 patients. Scand J Gastroenterol 1995; 30: 535-541
167. Jones VA, McLaughlan P, Shorthouse M, Workman E, Hunter JO. Food intolerance: a major factor in the pathogenesis of irritable bowel syndrome. Lancet 1982; 2: 1115-1117
168. Middleton SJ, Coley A, Hunter JO. The role of faecal Candida albicans in the pathogenesis of food-intolerant irritable bowel syndrome. Postgrad Med J 1992; 68: 453-454
169. Zwolinska-Wcislo M, Brzozowski T, Budak A, Kwiecien S, Sliwowski Z, Drozdowicz D, Trojanowska D, Rudnicka-Sosin L, Mach T, Konturek SJ, Pawlik WW. Effect of Candida colonization on human ulcerative colitis and the healing of inflammatory changes of the colon in the experimental model of colitis ulcerosa. J Physiol Pharmacol 2009; 60: 107-118
170. O'May GA, Reynolds N, Smith AR, Kennedy A, Macfarlane GT. Effect of pH and antibiotics on microbial overgrowth in the stomachs and duodena of patients undergoing percutaneous endoscopic gastrostomy feeding. J Clin Microbiol 2005; 43: 3059-3065
171. Loy CE. Antibiotic-associated diarrhoea: an overlooked aetiology? Br J Biomed Sci 2005; 62: 166-169
172. Song HJ, Shim KN, Jung SA, Choi HJ, Lee MA, Ryu KH, Kim SE, Yoo K. Antibiotic-associated diarrhea: candidate organisms other than Clostridium diffcile. Korean J Intern Med 2008; 23: 9-15
173. Maraki S, Mouzas IA, Kontoyiannis DP, Chatzinikolaou I, Tselentis Y, Samonis G. Prospective evaluation of the impact of amoxicillin, clarithromycin and their combination on human gastrointestinal colonization by Candida species. Chemotherapy 2001; 47: 215-218
174. Santelmann H, Howard JM. Yeast metabolic products, yeast antigens and yeasts as possible triggers for irritable bowel syndrome. Eur J Gastroenterol Hepatol 2005; 17: 21-26
175. Nosál R, Novotný J, Sikl D. The effect of glycoprotein from Candida albicans on isolated rat mast cells. Toxicon 1974; 12: 103-108
176. Noverr MC, Phare SM, Toews GB, Coffey MJ, Huffnagle GB. Pathogenic yeasts Cryptococcus neoformans and Candida albicans produce immunomodulatory prostaglandins. Infect Immun 2001; 69: 2957-2963
177. Reinholdt J, Krogh P, Holmstrup P. Degradation of IgA1, IgA2, and S-IgA by Candida and Torulopsis species. Acta Pathol Microbiol Immunol Scand C 1987; 95: 265-274
178. Simrén M, Stotzer PO. Use and abuse of hydrogen breath tests. Gut 2006; 55: 297-303
179. Khoshini R, Dai SC, Lezcano S, Pimentel M. A systematic review of diagnostic tests for small intestinal bacterial overgrowth. Dig Dis Sci 2008; 53: 1443-1454
180. Corazza GR, Menozzi MG, Strocchi A, Rasciti L, Vaira D, Lecchini R, Avanzini P, Chezzi C, Gasbarrini G. The diagnosis of small bowel bacterial overgrowth. Reliability of jejunal culture and inadequacy of breath hydrogen testing. Gastroenterology 1990; 98: 302-309
181. Ghoshal UC, Ghoshal U, Das K, Misra A. Utility of hydrogen breath tests in diagnosis of small intestinal bacterial overgrowth in malabsorption syndrome and its relationship with oro-cecal transit time. Indian J Gastroenterol 2006; 25: 6-10
182. Lin HC. Small intestinal bacterial overgrowth: a framework for understanding irritable bowel syndrome. JAMA 2004; 292: 852-858
183. Parodi A, Dulbecco P, Savarino E, Giannini EG, Bodini G, Corbo M, Isola L, De Conca S, Marabotto E, Savarino V. Positive glucose breath testing is more prevalent in patients with IBS-like symptoms compared with controls of similar age and gender distribution. J Clin Gastroenterol 2009; 43: 962-966
184. Lin HC, Pimentel M. Bacterial concepts in irritable bowel syndrome. Rev Gastroenterol Disord 2005; 5 Suppl 3: S3-S9
185. Majewski M, Reddymasu SC, Sostarich S, Foran P, McCal-lum RW. Efficacy of rifaximin, a nonabsorbed oral antibiotic, in the treatment of small intestinal bacterial overgrowth. Am J Med Sci 2007; 333: 266-270
186. Majewski M, McCallum RW. Results of small intestinal bacterial overgrowth testing in irritable bowel syndrome patients: clinical profiles and effects of antibiotic trial. Adv Med Sci 2007; 52: 139-142
187. Pimentel M, Chow EJ, Lin HC. Eradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel syndrome. Am J Gastroenterol 2000; 95: 3503-3506
188. Pimentel M, Chow EJ, Lin HC. Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome. a double-blind, randomized, placebo-controlled study. Am J Gastroenterol 2003; 98: 412-419
189. Pimentel M, Soffer EE, Chow EJ, Kong Y, Lin HC. Lower frequency of MMC is found in IBS subjects with abnormal lactulose breath test, suggesting bacterial overgrowth. Dig Dis Sci 2002; 47: 2639-2643
190. Husebye E. The pathogenesis of gastrointestinal bacterial overgrowth. Chemotherapy 2005; 51 Suppl 1: 1-22
191. Nieuwenhuijs VB, Verheem A, van Duijvenbode-Beumer H, Visser MR, Verhoef J, Gooszen HG, Akkermans LM. The role of interdigestive small bowel motility in the regulation of gut microfora, bacterial overgrowth, and bacterial trans-location in rats. Ann Surg 1998; 228: 188-193
192. Reddymasu SC, McCallum RW. Small intestinal bacterial overgrowth in gastroparesis: are there any predictors? J Clin Gastroenterol 2010; 44: e8-e13
193. Nakade Y, Fukuda H, Iwa M, Tsukamoto K, Yanagi H, Yama-mura T, Mantyh C, Pappas TN, Takahashi T. Restraint stress stimulates colonic motility via central corticotropin-releasing factor and peripheral 5-HT3 receptors in conscious rats. Am J Physiol Gastrointest Liver Physiol 2007; 292: G1037-G1044
194. Martnez V, Wang L, Rivier JE, Vale W, Tach Y. Differential actions of peripheral corticotropin-releasing factor (CRF), urocortin II, and urocortin III on gastric emptying and co-lonic transit in mice: role of CRF receptor subtypes 1 and 2. J Pharmacol Exp Ther 2002; 301: 611-617
195. Martinez V, Wang L, Million M, Rivier J, Tach Y. Urocortins and the regulation of gastrointestinal motor function and visceral pain. Peptides 2004; 25: 1733-1744
196. Million M, Maillot C, Saunders P, Rivier J, Vale W, Tach Y. Human urocortin II, a new CRF-related peptide, displays selective CRF(2)-mediated action on gastric transit in rats. Am J Physiol Gastrointest Liver Physiol 2002; 282: G34-G40
197. Guarner F, Malagelada JR. Gut flora in health and disease. Lancet 2003; 361: 512-519
198. Thorens J, Froehlich F, Schwizer W, Saraga E, Bille J, Gyr K, Duroux P, Nicolet M, Pignatelli B, Blum AL, Gonvers JJ, Fried M. Bacterial overgrowth during treatment with omeprazole compared with cimetidine: a prospective randomised double blind study. Gut 1996; 39: 54-59
199. Lewis SJ, Franco S, Young G, O'Keefe SJ. Altered bowel function and duodenal bacterial overgrowth in patients treated with omeprazole. Aliment Pharmacol Ther 1996; 10: 557-561
200. Spiegel BM, Chey WD, Chang L. Bacterial overgrowth and irritable bowel syndrome: unifying hypothesis or a spurious consequence of proton pump inhibitors? Am J Gastroenterol 2008; 103: 2972-2976
201. Gracely RH, Lynch SA, Bennett GJ. Painful neuropathy: altered central processing maintained dynamically by peripheral input. Pain 1992; 51: 175-194
202. http://www.functionalmedicine.org/about/whatis.asp accessed 9/12/2010